ONCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ONCO is not a good buy right now. The stock is still in a broader bearish trend (bearish moving-average stack), there are no Intellectia buy signals today, and there are no news catalysts to drive a near-term breakout. With an impatient entry mindset, the current setup does not offer an attractive risk/reward for a fresh buy at 1.49.
Price/Trend: The trend is bearish with SMA_200 > SMA_20 > SMA_5, signaling sustained downside pressure. Momentum: MACD histogram is positive (0.0176) but “positively contracting,” which typically suggests bullish momentum is fading rather than strengthening. RSI(6) at ~38.4 is weak/near the lower range but not a clear reversal signal. Levels: Pre-market 1.49 is sitting just above S1 (1.429). A break below ~1.43 increases downside risk toward S2 (1.221). Upside would likely face overhead resistance around the pivot (1.765) and R1 (2.101). Pattern-based outlook: Similar-pattern stats imply only marginal upside next day/week and a negative bias over the next month (-2.05%), which does not support an aggressive buy now.
Intellectia Proprietary Trading Signals
Gross margin improved significantly in 2025/Q3 (88.55%, up sharply YoY), which can be supportive if it reflects sustainable cost structure improvements.
Price is near a defined support zone (around 1.43), which can sometimes create a short-term technical bounce.
MACD remains slightly positive, indicating the prior bounce attempt hasn’t fully disappeared yet.
and EPS deterioration (EPS down -97.49% YoY), consistent with fundamental pressure.
Latest reported quarter: 2025/Q3. Revenue: 303,651, down -25.37% YoY (negative growth trend). Net income: -8,783,702 (loss). It is shown as “increased” YoY, but it remains deeply negative, indicating ongoing profitability issues. EPS: -6.25, down -97.49% YoY (material deterioration). Gross margin: 88.55%, up sharply YoY—one bright spot, but it has not translated into profitability given the large net loss.
No analyst rating or price target change data was provided, so there’s no clear Wall Street consensus shift to lean on. Pros (if any) would likely center on margin improvement and potential turnaround optionality; cons are the lack of visible growth (revenue down), ongoing large losses, and a still-bearish technical trend—making the risk case dominate right now.
